Core Viewpoint - Haier Biomedical has transformed from a single low-temperature storage manufacturer to a comprehensive life sciences and medical innovation enterprise, with significant growth in new industries contributing to revenue [1][2]. Group 1: Financial Performance - In the first half of 2025, Haier Biomedical achieved operating revenue of 1.196 billion yuan and a net profit attributable to shareholders of 143 million yuan [1]. - The revenue share from new industries (smart medication, blood technology, laboratory solutions) increased from 38% in 2023 to 47% in 2025, a year-on-year increase of 7.27 percentage points [1][2]. Group 2: Industry Position and Innovations - The company holds over 50% market share in plasma collection solutions, maintaining its position as the leader in China [2]. - Haier Biomedical has upgraded its business model from "single equipment sales" to a comprehensive approach that includes smart devices, basic consumables, software platforms, and value-added services, enhancing customer loyalty and profitability [2]. Group 3: Research and Development - The company’s R&D investment increased by 11.61% year-on-year, accounting for 13.39% of operating revenue, focusing on AI technology integration and new product development [2]. Group 4: Market Expansion - Haier Biomedical's products are now available in over 150 countries and regions, with a 30% year-on-year increase in overseas revenue during the reporting period [3]. - The company has established localized platforms in five new countries, including Japan and Brazil, and anticipates growth in overseas markets due to the acceleration of medical infrastructure development in emerging markets [3].